#United States #Skincare #Crown Laboratories #Johnson City #Revance

Crown Laboratories Completes Revance Therapeutics Acquisition

Crown Laboratories, Inc., a private global leader in skincare, announced the conclusion of its acquisition of Revance Therapeutics, a company known for setting new standards in healthcare through innovative aesthetic and therapeutic offerings. This strategic merger positions Crown as a formidable player in the aesthetics and skincare market, further enhancing its growth trajectory.

Details of the Acquisition

The acquisition process began with Crown's tender offer for Revance’s stock priced at $3.65 per share. This offer was put forth for all outstanding shares, and the deadline was set for February 4, 2025. As the deadline approached, Crown received a favorable response, with over 86 million shares tendered, which accounted for approximately 82% of Revance's total issued shares. Following this response, Crown exercised its rights to purchase all validly tendered shares, leading to the completion of the acquisition through a second-step merger.

As part of this transition, Revance's common stock will now be removed from the NASDAQ, a significant step that reflects a new phase in the company’s operations under Crown’s leadership.

Strategic Impact

This merger is expected to significantly bolster Crown’s portfolio of skincare products, expanding opportunities within the aesthetic and therapeutic markets. By combining resources and expertise, Crown aims to push the limits of skincare innovation, emphasizing therapeutic efficacy and enhanced patient outcomes. The acquisition underscores Crown’s continuous commitment to delivering state-of-the-art products and staying ahead in a highly competitive industry.

Financial Advisory Team

Crown enlisted the help of seasoned advisors to navigate this complex acquisition. Leerink Partners and PJT Partners acted as financial advisors, while legal representation was provided by Kirkland & Ellis LLP and Lowenstein Sandler LLP. This expert guidance has been pivotal in ensuring a seamless transaction process.

About Crown Laboratories

Founded with a mission to improve the quality of life through innovative skincare solutions, Crown Laboratories is committed to developing a diverse range of premium products appealing to both aesthetic and therapeutic markets. With a strong emphasis on skin science, Crown’s portfolio boasts well-known brands that are widely recognized in the dermatology arena, such as PanOxyl and Blue Lizard.

Crown's impressive growth has not gone unnoticed, as the company has been listed on the Inc. 5000 Fastest Growing Privately Held Companies for eleven consecutive years and has expanded its reach to over 50 countries globally. This acquisition only strengthens Crown’s position in the market and supports its vision of creating skincare solutions that truly make a difference.

Looking Ahead

As Crown Laboratories integrates Revance Therapeutics into its operations, stakeholders remain optimistic about the future. The merger is anticipated to unlock a wealth of synergies and innovative capabilities that strengthen product offerings and market position. With a robust pipeline, Crown is poised for substantial growth in the aesthetics and skincare sectors, continually pushing towards new frontiers in skincare science.

In closing, Crown’s acquisition of Revance is more than just a merger of assets; it signifies a new era in enhancing patient care and setting elevated standards within the skincare industry. As both companies merge their expertise, the future looks bright for both Crown and its consumers, marking a pivotal milestone in advancing skincare solutions.

For more information about Crown Laboratories and its newly acquired products, visit Crown Laboratories.